QUOTED. 6 September 2019. Evan Jones.
Gaithersburg, MD-based OpGen and Amsterdam-based Curetis NV plan to merge to become a transatlantic molecular diagnostics and bioinformatics company focused on infectious disease and microbial resistance. See what Evan Jones, OpGen's CEO, said about it here.
"The combination of OpGen and Curetis will help maximize value for our stockholders and will result in an organization with a robust pipeline of molecular diagnostic and bioinformatics products, significant management experience, and proprietary assets for developing and commercializing novel data-driven solutions in infectious disease diagnostics." – Evan Jones, CEO, OpGen
- Find out more: Molecular Diagnostic Firms Curetis And OpGen Announce Merger
Click here for a free trial of Medtech Insight